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BACKGROUND: Therapies targeting ERBB2 have shown success in the clinic. However, response is not determined solely by expression
of ERBB2. Levels of ERBB3, its preferred heterodimerisation partner and ERBB ligands may also have a role.
METHODS: We measured NRG1 expression by real-time quantitative RT–PCR and ERBB receptors by western blotting and
immunohistochemistry in bladder tumours and cell lines.
RESULTS: NRG1a and NRG1b showed significant coordinate expression. NRG1b was upregulated in 78% of cell lines. In tumours,
there was a greater range of expression with a trend towards increased NRG1a with higher stage and grade. Increased expression of
ERBB proteins was detected in 15% (EGFR), 20% (ERBB2), 41% (ERBB3) and 0% (ERBB4) of cell lines. High EGFR expression
was detected in 28% of tumours, associated with grade and stage (P¼0.05; P¼0.04). Moderate or high expression of ERBB2 was
detected in 22% and was associated with stage (P¼0.025). Cytoplasmic ERBB3 was associated with high tumour grade (P¼0.01)
and with ERBB2 positivity. In cell lines, NRG1b expression was significantly inversely related to ERBB3, but this was not confirmed in
tumours.
CONCLUSION: There is a wide spectrum of NRG1 and ERBB receptor expression in bladder cancer. In advanced tumours,
EGFR, ERBB2 and ERBB3 upregulation is common and there is a relationship between expression of ERBB2 and ERBB3 but not the
NRG1 ligand.
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Bladder cancer is the fourth most common malignancy in males
and the ninth most common in females in the United Kingdom,
with 10090 new cases in 2007 (http://info.cancerresearchuk.org/
cancerstats/types/bladder/incidence/). At presentation, 70–80%
of patients have non-muscle-invasive urothelial carcinoma (UC;
stage Ta or T1) and 20–30% have invasive disease (Xstage T2).
For the latter, 5-year survival rate is B50% and, although current
chemotherapy and radiotherapy regimes are effective in some
patients, response rates have plateaued and novel therapeutic
approaches are urgently needed.
Overexpression of the ERBB receptor tyrosine kinases in human
cancer has led to the development of targeted therapies (Hynes and
Lane, 2005). ERBB2 is overexpressed in 20–30% of breast cancers,
and the monoclonal antibody Trastuzumab (Herceptin) that
targets ERBB2 has been used with success to treat these (Slamon
et al, 2001). As some bladder tumours overexpress ERBB2
(Chow et al, 2001), it has been suggested that these may respond
to ERBB2 inhibitors (Latif et al, 2004) and therefore clinical studies
have been initiated (Small et al, 2003). A study of Trastuzumab,
paclitaxel, carboplatin and gemcitabine in advanced ERBB2-
positive UC has been reported, with an overall response rate of
70% (Hussain et al, 2007). However, a randomised trial is
required to assess the contribution of Trastuzumab to such
responses. A phase I/II study of paclitaxel and radiotherapy, with
or without Trastuzumab, is now underway in patients who
have undergone previous resection for muscle-invasive UC
(NCT00005831).
Not all breast cancers that overexpress ERBB2 respond to
Trastuzumab (Vogel and Franco, 2003). In some cases, lack of
response is related to downstream activation of the PI3K pathway
through mechanisms such as PTEN inactivation (Nagata et al,
2004). ERBB3 is known to couple ERBB2 to the PI3K pathway
(Junttila et al, 2009) and the crucial role of ERBB3 in mediating
the effects of activated ERBB2 is now clear (Lee-Hoeflich et al,
2008; Baselga and Swain, 2009). Altered expression of the
ligand neuregulin may also determine sensitivity to ERBB2 inhi-
bitors and identify a novel group of patients who could
benefit from ERBB-targeted therapies (Yuste et al, 2005; Menendez
et al, 2006).
Neuregulin 1 (NRG1) is a member of the epidermal growth
factor (EGF) family (Yarden, 2001). At least 10 NRG1 isoforms
have been identified (Stove and Bracke, 2004) (Supplementary
Figure 1). Types I, II and III have distinct amino termini that
contain an Ig-like domain in types I and II (Li and Loeb, 2001).
The N terminus of type III isoforms contains a cysteine-rich
domain with a transmembrane domain. All isoforms contain an
EGF-like domain, which is essential (and sufficient) for receptor
activation (Alroy and Yarden, 1997). Alternative splicing in this
domain gives rise to a- and b-variants. Alternative splicing in
the extracellular juxtamembrane region gives rise to four further
variants. Finally, alternative splicing in the cytoplasmic tail
(C-terminal) leads to a, b or c variants.
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higher affinity than NRG1a (Jones et al, 1999). As there is
no ligand for ERBB2, heterodimerisation with a ligand-bound
receptor is required for signalling (Klapper et al, 1999), and ERBB2
is the preferred binding partner for other ligand-bound ERBB
receptors (Garrett et al, 2003; Franklin et al, 2004). As ERBB3 is
devoid of intrinsic kinase activity, it requires dimerisation with
another ERBB receptor for phosphorylation (Guy et al, 1994) and
ERBB2–ERBB3 heterodimers provide the most mitogenic and
angiogenic signals (Alimandi et al, 1995).
Increased expression of NRG1 proteins has been reported
in several cancers. However, there is little data on expression in
normal urothelium or bladder tumours and reports are incon-
sistent. De Boer et al (1997) showed that expression of different
NRG1 isoforms varied in different cell layers of the normal and
malignant bladder. In the normal urothelium, expression of
NRG1a and NRG1b1 isoforms was highest in the differentiated
superficial cells and NRG1a and NRG1b mRNA was detected in
90 and 61% of tumours, respectively, with a negative trend between
NRG1b expression and survival (Memon et al, 2004). In contrast,
Amsellem-Ouazana et al (2006) did not detect NRG1 in 5 normal
bladder and 73 tumour samples.
NRG1 maps to chromosome arm 8p, a region of common
genomic alteration in human tumours including bladder. Loss of
heterozygosity (LOH) of 8p is found in muscle-invasive UC
(Wagner et al, 1997; Ohgaki et al, 1999; Choi et al, 2000), and in
bladder and other tumour types 8p LOH is associated with worse
prognosis. In breast cancer, several breakpoints have been
identified close to or within NRG1 (Huang et al, 2004) and recent
identification of promoter hypermethylation suggests a possible
suppressor role (Chua et al, 2009). However, upregulation has also
been reported (McIntyre et al, 2009).
The reported expression of the ERBB family of receptors in
normal and malignant bladder also differs markedly between
studies, and these are difficult to compare because of differences in
methods, antibodies and scoring criteria. Before ERBB-targeted
therapies can be rationally applied in bladder cancer, clear data on
the expression of the different receptors and relevant ligands are
required. The objectives of this study were to determine expression
of the two major isoforms of NRG1 and the ERBB family
of receptors in human bladder cancer cell lines and tumour
tissues. We have applied the criteria used for scoring of ERBB2
immunohistochemistry in breast cancer to obtain standardised
assessment of expression and hence a more rational prediction of
the proportion of bladder cancer patients who may benefit from
ERBB2-targeted therapy.
MATERIALS AND METHODS
Patient recruitment and tissue collection
Ethical approval was obtained from the Leeds (East) Local
Research and Ethics Committee, and informed consent for tissue
donation was obtained from patients at St James’s University
Hospital, Leeds. Tumour tissues obtained by cold-cup biopsy at
cystoscopy or from cystectomy were snap-frozen. Fifty-nine fresh
samples were used (23 pTaG2; 4 pTaG3; 5 pT1G2; 14 pT1G3; 10
pT2G3; and 3 T4G3).
Cell lines
Primary normal human urothelial cells (NHUC) and telomerase
immortalised NHUC (TERT-NHUC) were maintained as
described (Chapman et al, 2006). Thirty-four UC cell lines
(Supplementary Table 1) were grown in standard media at 371C
in 5% CO2.
mRNA extraction and cDNA preparation
RNA was extracted from cell lines using the RNeasy mini kit
(Qiagen, Crawley, UK), and from tissue sections containing 480%
tumour cells using the Picopure RNA isolation kit (Arcturus
Bioscience, Mountain View, CA, USA). For cDNA synthesis, the
Clontech Advantage 1st strand kit (Clontech, Palo Alto, CA, USA)
was used.
Quantitative real-time RT–PCR
Quantitative RT–PCR (qRT–PCR) used SYBR Green I as reporter
and ROX as reference dye (Perkin-Elmer, Applied Biosystems,
Cheshire, UK). Fluorescence was detected by an ABI prism 7700
Sequence Detection System (Applied Biosystems) and analysed
using the Sequence Detector System 1.9 software (Applied
Biosystems). Succinate dehydrogenase (SDHA) and hypoxanthine
phosphoribosyl-transferase1 (HPRT1) were used as controls.
Primers were designed using Primer Express software (Applied
Biosystems; Supplementary Table 2). Preliminary experiments
over a range of concentrations of reverse transcribed Universal
reference RNA (Stratagene, La Jolla, USA) were conducted to
determine the efficiency of the PCR reaction for each set of primers
and the comparative CT (DDCT) method was used for analysis
(Livak and Schmittgen, 2001). The cDNA from pooled pure
populations of uncultured normal human urothelial cells was used
as a control for cell line analysis.
Western blotting
Cells were lysed in ESB buffer (0.12M Tris-HCL, pH 6.8; 20%
glycerol; 4% SDS) and protein concentration measured using the
Pierce Protein Assay (Rockford, IL, USA). Antibodies used were
anti-EGFR (1005 sc-03 Santa Cruz, Santa Cruz, CA, USA), ERBB2
(A0485 Dako Cytomation, Ely, UK), ERBB3 (c-17 sc-285
Santa Cruz) and ERBB4 (RB-284 Labvision, Fremont, CA, USA).
Anti-Ku-70 (Santa Cruz) was used as a loading control. For
quantification, films were scanned on a Personal Densitometer SI
(Molecular dynamics/Amersham Biosciences, Little Chalfont, UK)
and band densities were calculated with ImageQuant software
(Molecular dynamics/Amersham Biosciences).
Immunohistochemistry
Fifty-four paraffin-embedded tumour tissues were studied. Three
normal ureters and cell line pellets known to be positive or
negative for each antigen were used as controls. For ERBB2,
a strongly positive breast cancer tissue was used as a control in
each run.
Endogenous peroxidase activity was blocked in 3% hydrogen
peroxide, sections were boiled in antigen unmasking solution
(Vector Laboratories, Peterborough, UK) for 2min (EGFR and
ERBB2) and blocked with either 10% (v/v) casein (ERBB2) or
avidin/biotin solutions (Vector Laboratories) (other antigens),
followed by treatment with 10% normal goat serum (Dako
Cytomation). Primary antibodies for EGFR (NCL-EGFR-384,
Novocastra, Newcastle, UK), ERBB2 (A0485, Dako Cytomation),
ERBB3 (RTJ2 (Rajkumar et al, 1995); supplied by Cancer Research
UK) and ERBB4 (c-18 sc-283 Santa Cruz) were applied for 60min.
Following incubation with Envision (Dako Cytomation) (ERBB2)
or secondary anti-species antibody, followed by treatment with
Streptavidin–biotin enzyme complex (StreptAB-Complex, Dako
Cytomation), binding was visualised using 3,30diamino-benzidine
tetrahydrochloride (Vector Laboratories).
Scoring was performed by JF, PH and MK. In the absence of
full concordance, slides were reviewed and a decision taken.
Membrane staining was considered as positive for EGFR and
ERBB2. For ERBB3, membrane staining was not observed and
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criteria for EGFR and ERBB2 were as used for ERBB2 in breast
cancer tissues and a multitissue breast reference section was used
to guide scoring (0, no membrane staining; 1þ, weak membrane
staining only; 2þ, strong membrane staining in some cells; 3þ,
strong membrane staining in all cells). For ERBB3, initial scoring
for cytoplasmic and nuclear staining was according to both
intensity and frequency (weak, moderate, strong; o5%, 5–50%,
450% of cells). This was subsequently refined for cytoplasmic
staining to score as positive tumours in which 45% of cells
showed moderate or strong staining, and for nuclear staining to
score those in which 450% of cells showed moderate or strong
staining.
Statistical analysis
The statistical software Stata (v10, StataCorp, College Station, TX,
USA) was used for data handling and analyses. The relationship
between NRG1a and NRG1b expression and between NRG1a/b and
EGFR/ERBB2/ERBB3 expression was assessed using Spearman’s
rank correlation. The Mann–Whitney test was used to assess the
relationships between NRG1a/b expression and tumour stage (Ta
compared with XT1 tumours) and grade (grade 2 compared with
grade 3). Fisher’s exact test was used to assess the relationship
between tumour grade and stage and immunohistochemistry
score.
RESULTS
NRG1 expression in normal urothelium, UC cell lines and
tumours
Quantitative RT–PCR on uncultured urothelial cells isolated from
five normal healthy ureters and a pooled sample composed of
equal amounts of these samples showed no significant differences
in expression of NRG1a and NRG1b (Supplementary Figure 2). In
all samples, levels of both isoforms were lower than levels of the
control genes.
NRG1a and NRG1b expression in 32 UC cell lines relative to
cultured NHUC controls is shown in Figure 1. There was
significant coordinate expression of the two isoforms (Spearman’s
rank correlation 0.889; Po0.001). Overall, NRG1b showed higher
expression than NRG1a and was upregulated more frequently.
Twenty-five of 32 cell lines showed NRG1b levels X1.5 higher than
controls, and in several cases the levels were 50- to 100-fold higher.
Quantitative RT–PCR on cDNA from 59 tumours revealed more
varied expression levels than in cell lines, ranging from
undetectable in some tumours to 770-fold higher expression of
NRG1b in one tumour compared with normal urothelium
(Figure 2). Although NRG1b was more highly expressed than
NRG1a, this was not as significant as in cell lines. As in cell lines,
there was a statistically significant correlation between expression
of NRG1a and NRG1b (Spearman’s rank correlation, r¼0.680,
Po0.0001). There was a tendency for NRG1a upregulation in high-
grade and stage tumours, although this did not reach significance
(for grade P¼0.08, Mann–Whitney test; for stage P¼0.06,
Spearman’s rank correlation test). There was no significant
relationship between NRG1b and grade or stage (for grade
P¼0.44, Mann–Whitney test; for stage P¼0.13, Spearman’s rank
correlation test).
We have detailed information on 8p genomic alterations in all of
the cell lines studied (Williams et al, 2010). Expression of NRG1
bore no obvious relationship to either copy number in the region
of the gene or to breakpoints in the region.
ERBB protein expression
Autocrine signalling generated through NRG1 expression even in
the presence of low-level receptor expression may have the same
cellular consequences as high-level receptor expression. We
examined levels of EGFR, ERBB2, ERBB3 and ERBB4 in UC cell
lines for comparison with NRG1 levels (Figure 3 and Supplemen-
tary Figure 3).
High-level expression of EGFR (X2-fold, relative to normal
urothelial control) was found in five cell lines, moderate
expression (0.1–1.99 control) in 25 and absent or low expression
(p0.1 control) in four. Moderate levels of ERBB2 were detected
in 16 cell lines and low levels in 18 cell lines. ERBB3 showed strong
expression in 14, moderate expression in 9 and low levels in 11 cell
lines. Western blots for ERBB4 demonstrated a single strong band
at the predicted size for the full-length ERBB4 protein (180kDa)
only in the breast cancer cell line T47D-positive control (Beerli and
Hynes, 1996). No expression of ERBB4 was detected in any of the
bladder cancer cell lines or in normal bladder samples. Relation-
ships were sought between expression of NRG1a and NRG1b and
expression of EGFR, ERBB2 and ERBB3 in UC cell lines. There was
an inverse correlation between both NRG1a and NRG1b expres-
sion and ERBB3 expression (Pp0.01, Spearman’s rank correlation
test). No other significant relationships were found.
Immunohistochemistry was performed on 54 tumours from the
same series as those used for mRNA analysis (Table 1; Figure 4).
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Figure 1 Real-time RT–PCR measurements of NRG1a and NRG1b levels in bladder cell lines. Results are expressed relative to a pooled normal
urothelial cell RNA sample (1). Cell lines analysed: 2, VMCUBIII; 3, JO’N; 4, HT1376; 5, HT1197; 6, DSH1; 7, 647V; 8, RT4; 9, 97-29; 10, 97-24; 11, 94-10;
12, KU19-19; 13, JMSU1; 14, RT112; 15, 96-1; 16, SD; 17, CAL29; 18, 97-6; 19, SCaBER; 20, 97-18; 21, 97-7; 22, T24; 23, 5637; 24, 97-1; 25, VMCUBII; 26,
J82; 27, UMUC3; 28, 253J; 29, BFTC905; 30, TCCSUP; 31, BFTC909; 32, SW1710; 33, BC3C. Inset shows the range of expression of NRG1a and b as a
boxplot. Horizontal line indicates median value.
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Figure 3 Expression levels of EGFR, ERBB2 and ERBB3 in bladder cell lines. Results represent densitometric measurements of western blot signals relative
to ku70 loading control.
Table 1 Expression of EGFR, ERBB2 and ERBB3 in bladder tumours according to stage and grade
EGFR ERBB2 ERBB3 cytoplasmic ERBB3 nuclear
Stage/grade 1+ (%) 2+ (%) 3+ (%)   (%) 1+ (%) 2+ (%) 3+ (%)   (%) + (%) 0 (%) + (%)
G2 8 (33.33) 11(45.83) 5 (20.53) 9 (37.5) 13 (54.17) 2 (8.33) 0 20 (83.33) 4 (16.67) 11 (45.83) 13 (54.17)
G3 2 (6.67) 18 (60.0) 10 (33.33)
a 6 (20.0) 14 (46.67) 8 (26.67) 2 (6.67) 14 (46.67) 16 (53.33)
b 17 (56.67) 13 (43.33)
Ta 8 (34.78) 10 (43.48) 5 (21.74) 9 (39.13) 11 (47.83) 3 (13.04) 0 16 (69.57) 7 (30.43) 10 (43.48) 13 (56.52)
T1 2 (11.11) 12 (66.67) 4 (22.22) 1 (5.56) 11 (61.11) 6 (33.33) 0 11 (61.11) 7 (38.89) 10 (55.56) 8 (44.44)
XT2 0 6 (50.0) 6 (50.0)
c 4 (33.33) 5 (41.67) 1 (8.33) 2 (6.67)
d 6 (50.0) 6 (50.0) 7 (58.33) 5 (41.57)
aP¼0.05.
bP¼0.01.
cWhen invasive tumours (T1+XT2) grouped P¼0.04.
dP¼0.025 when Ta, T1 and XT2 analysed separately; P¼0.225 when invasive tumours (T1+XT2)
grouped.
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Figure 2 Real-time RT–PCR measurements of NRG1a and NRG1b levels in tumour samples. Results are expressed relative to a pooled normal
urothelial cell RNA sample (N). Samples are grouped according to tumour grade and stage. K, no expression detected; *, samples that showed high levels
of expression of ERBB2. Inset shows the range of expression of NRG1a and b as a boxplot. Horizontal line indicates median value.
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Figure 4 Immunohistochemistry for EGFR and ERBB2 in bladder tumour samples. (A) EGFR þ;( B) EGFR þþþ;( C) ERBB2 negative sample
(cell pellet from non-expressing cell line); (D) ERBB2 þ;( E) ERBB2 þþ;( F) ERBB2 þþþ;( G) ERBB3 nuclear þ; and (H) ERBB3, cytoplasmic þ.
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detected in the cell membranes of all tumours, 54% of which
showed moderate (2þ) and 28% showed strong (3þ) staining.
Increased expression was associated with high grade (Fisher’s
exact test, P¼0.05). A marginal association with tumour stage was
found when Ta, T1 and XT2 tumours were considered separately
(P¼0.06), and this reached significance (P¼0.04) when tumours
were grouped as non-invasive (Ta) or invasive (T1 or XT2).
ERBB2 membrane staining was detected in 72%, the majority
having weak or patchy staining. There was no relationship with
grade (P¼0.12). An association with stage was found (P¼0.025)
but the pattern of this was not clear as results for T1 and XT2
tumours differed and significance was lost when these two groups
were combined.
ERBB3 expression was detected in the nucleus, the cytoplasm or
both (Figure 4) and was scored separately. There was strong
association between tumour grade and cytoplasmic staining
(P¼0.01) but no relationship with nuclear staining (P¼0.58).
There was no association between stage and cytoplasmic or
nuclear staining, although there was a trend for more frequent
cytoplasmic staining and less frequent nuclear staining with
increasing stage. There was no association between cytoplasmic
staining or nuclear staining and tumour invasion (P¼0.40 and
0.41, respectively). Overall, there was an association between
nuclear staining and cytoplasmic staining (P¼0.02) with overall
concordance for staining (either both positive or both negative as
compared with discordant staining). This pattern could be seen
when non-invasive (Ta) and invasive (T1 or XT2) tumours were
analysed separately but in neither case did the association reach
significance because of limited sample sizes. Logistic regression
analysis of the presence of cytoplasmic staining or nuclear staining
showed that there was still evidence for concordance (P¼0.01)
after adjustment for invasion. We also examined the relationship
of the four possible patterns of ERBB3 staining with grade and
stage. There was no relationship with tumour stage but a
significant association with grade (P¼0.01; Supplementary
Table 3) was observed. There was evidence of an association
between cytoplasmic ERBB3 and ERBB2 positivity (P¼0.04), but
not between nuclear ERBB3 and ERBB2 or between any other
ERBB receptor pairs.
Anti-ERBB4 antibodies showed poor specificity on cell pellets
with known ERBB4 expression status. Newly constructed cell
pellets and different normal tissue samples gave the same results.
Therefore, staining was not carried out on tumour sections.
The relationship of NRG1a and NRG1b mRNA levels to
expression of EGFR, ERBB2 and ERBB3 (cytoplasmic or nuclear
staining) was examined. No statistically significant associations
were found (Spearman’s rank correlation test).
DISCUSSION
ERRB receptor signalling is diverse and flexible in output because
of the presence of multiple receptors that homo- or hetero-
dimerise and the existence of multiple ligands. Thus, there is much
scope for subversion to provide selective advantage in cancer
cells. Targeting of overexpressed ERBB2 with the humanised
monoclonal antibody Trastuzumab has proven successful in some
cases. However, in light of the flexibility of this signalling system, it
is not surprising that ERBB2 status alone is not sufficient to predict
response. Similarly, expression level of EGFR does not predict
response to EGFR inhibitors, although the presence of mutations
in the receptor shows correlation with response (Lynch et al, 2004;
Rosell et al, 2006). It is not yet clear whether mutations in ERBB2
(Stephens et al, 2004) influence response to ERBB2 inhibitors.
Increasingly, it is becoming apparent that the overall molecular
context in which such mutations are found significantly influences
response to targeted therapies, with molecular lesions downstream
of EGFR or ERBB2 indicating likely resistance (Nagata et al, 2004;
Allegra et al, 2009). Similarly, the status of interacting proteins
including different members of the ERBB family and their ligands
may profoundly influence response.
Prompted by the finding of common genomic alterations in the
region of the NRG1 gene on 8p12 in aggressive bladder cancers and
other solid malignancies, as well as the known overexpression of
EGFR and ERBB2 in some bladder tumours, we examined the
expression of NRG1 mRNA and protein expression of EGFR,
ERBB2, ERBB3 and ERBB4 in bladder tumour tissues and cell lines.
There was considerable diversity in the expression of NRG1
in both cell lines and in tumours with higher expression of NRG1b
than NRG1a, suggesting, as proposed previously, that the
b-isoform may be more biologically important (Lu et al, 1995).
Overall, tumour tissues showed lower levels of expression than cell
lines. Although there was a trend towards upregulation of NRG1b
in relation to grade and stage, there was no clear relationship with
expression of NRG1b because of the finding of relatively high
levels of expression of NRG1b in some pTaG2 tumours (Figure 2).
As all of the cell lines apart from RT4 were derived from invasive
tumours, and NRG1b was high in these, this suggests that
increased expression is related to tumour stage. This may become
clearer when a larger tumour panel is studied. The possibility that
pTaG2 tumours that overexpress NRG1b may represent a distinct
subset must also be addressed.
Others have found loss of expression and hypermethylation of
the NRG1 promoter in breast cancer cell lines that, similar
to bladder, commonly show 8p alterations (Chua et al, 2009). We
found no relationship of expression levels to known genomic
alterations (Williams et al, 2010) in the cell lines examined here.
Although this suggests that copy number alterations and DNA
breakpoints close to NRG1 do not affect expression, this does not
preclude the possibility that in some cases downregulated
expression (for example, tumours 1–9, Figure 1) may be caused
by promoter hypermethylation.
A previous study detected NRG1a and NRG1b mRNA in 90%
and 61% of samples, respectively, rates that are remarkably similar
to those found here (83 and 66%, respectively; Figure 2) and, as
in the present study, levels of NRG1b were higher than those of
NRG1a (Memon et al, 2004). One difference is that the primers
used to amplify NRG1b by Memon et al (2004) are predicted to
amplify types I and II but not III and the primers we used amplify
all three NRG1 types. The similarity in results obtained with these
two primer sets suggests that type III neuregulins, which are
predicted to mediate juxtacrine rather than paracrine signalling
(Falls, 2003), are unlikely to have a significant role in the
urothelium.
We found significant coexpression of NRG1a and NRG1b.
The transcriptional regulation of NRG1 is not yet understood but it
is possible that these transcripts share the same 50 sequence and
are initiated from the same promoter. Further analysis of the
type-specific region, Ig-like regions and spacer sequences that lie
upstream of the EGF domain are now required.
There are approximately 20 commercially available antibodies
that claim either to be specific to certain isoforms, or to detect
all types of NRG1 by means of epitopes in the EGF domain.
We attempted to measure NRG1 expression using western blotting
with three different NRG1 antibodies, but results were poor, with
multiple bands observed that were thought to be non-specific and
showed no obvious relationship to mRNA data (data not shown).
Several large studies of EGFR expression using immunohisto-
chemistry are concordant and report detectable levels in 72, 85, 96
and 84% of bladder tumour tissues (Messing, 1990; Wright et al,
1991; Lipponen and Eskelinen, 1994; Chow et al, 2001) and
moderate or strong EGFR expression has been described in 27, 52,
42 and 47% of tumours (Lipponen and Eskelinen, 1994; Mellon
et al, 1995; Chow et al, 2001; Rotterud et al, 2005). We detected
expression in all samples and this was moderate or strong in 28%.
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expression as different cut-offs and definitions for ‘expression’ and
‘overexpression’ have been used. The scoring method used here for
both EGFR and ERBB2 scoring was chosen because it is extensively
and successfully used for ERBB2 in breast cancers in the United
Kingdom. We found significantly more intense membrane staining
for EGFR in tumours of high grade and stage. Previous studies
have reported increased expression in tumours of high grade
(Messing, 1990), increased stage (Chow et al, 1997) or high grade
and stage (Wright et al, 1991; Mellon et al, 1995) but others have
not (Rajkumar et al, 1996; Rajjayabun et al, 2005).
We found ERBB2 membrane staining in the superficial cells of
the normal bladder and ureter and in 72% of tumour tissues.
Although moderate (2þ) staining was common, only three cases
had strong (3þ) expression. Similarly, although protein was
detected in 47% of cell lines, none had high-level expression. Data
on ERBB2 immunohistochemistry in bladder cancer are plentiful
and a variety of antibodies, methods and scoring techniques have
been used. One recent study applied a standardised methodology
used in breast tumour diagnostic assessment to measure both gene
amplification and expression of ERBB2 (Lae et al, 2010). Only a
few tumours (5%) expressed levels as high as those that are used to
select breast cancers for Trastuzumab treatment (3þ). Our finding
of 5.5% is compatible with this. We found no significant
relationship between ERBB2 expression and tumour grade but
an association with tumour invasion was apparent.
We found detectable ERRB3 by western blotting in normal
urothelial cells and in 68% of tumour cell lines, with high levels
in 41%. Immunohistochemistry of tumour tissues has previously
found moderate or strong ERBB3 expression in 11–49%
(Rajkumar et al, 1996; Chow et al, 1997, 2001; Rotterud et al,
2005). Here we scored cytoplasmic and nuclear staining
separately and found that 37 and 48% of tumours were positive,
respectively. Cytoplasmic staining was associated with tumour
grade as observed previously (Chow et al, 2001). There was also an
association with ERBB2 positivity (P¼0.04). Previously, a
relationship of ERBB2 and ERBB3 positivity has been reported to
be associated with poor patient survival and may indicate a role for
signalling by ERBB2/3 heterodimers (Chow et al, 2001).
The significance of nuclear vs cytoplasmic localisation of ERBB3
protein is not clear. It has been reported that the protein is nuclear
in cultured normal mammary epithelial cells and that stimulation
with NRGb1 causes shuttling to the cytoplasm (Offterdinger et al,
2002). We did not observe nuclear staining in normal urothelium
and found no evidence for increased cytoplasmic staining
in tumours with higher levels of NRG1 expression. In contrast,
in prostate tissues, nuclear ERBB3 is reported only in cancer
tissues and not in normal tissues, increasing with Gleason grade
and disease recurrence (Koumakpayi et al, 2006, 2007). Here we
found no association of nuclear staining with either grade or stage.
A larger study is merited to establish the significance of these
different staining patterns in bladder cancer.
NRG1 expression was inversely related to ERBB3 expression in
UC cell lines. This could indicate that expression of either
the ligand or the receptor may be important. Indeed, of the seven
cell lines with greatest total NRG1 expression shown in Figure 1, all
but one (SW1710) show very low or undetectable levels of
either ERBB2 or ERBB3. This may identify the presence of an
NRG1–ERBB3/ERBB2 autocrine loop in these cases as in other
tumour cell types (Gilmour et al, 2002; Venkateswarlu et al, 2002;
Li et al, 2004; Sheng et al, 2010), and could indicate that very low
levels of receptor expression may be sufficient for signalling. This
relationship was not seen in tumours, although it should be noted
that the UC cell lines used were derived from invasive tumours and
may represent a highly selected subgroup. Therefore, analysis of a
much larger group of invasive tumours is merited.
Already, it is clear that expression of NRG can influence tumour
response to Herceptin. Knowledge of ligand expression status will
also be critically important in assessing likely response to agents
such as Pertuzumab that interfere with ligand-dependent signal-
ling through ERBB2 (Agus et al, 2002). Our finding that NRG1
expression is higher in tumours of high grade and stage may be
particularly relevant in this context, as these are tumours for which
targeted therapies are most urgently needed. In conclusion, our
results suggest that NRG1–ERBB receptor interactions may have a
significant role in the pathogenesis of bladder cancer and are
potential targets for therapy. The identification of tumour cell
lines with different patterns of expression of these proteins
now provides the opportunity to carry out functional analyses to
test this.
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